Yang Chia-Wei, Yen Hsu-Heng, Su Wei-Wen, Chen Yang-Yuan, Soon Maw-Soan
Department of Gastroenterology, Changhua Christian Hospital, Changhua County, Taiwan.
South Med J. 2010 Dec;103(12):1264-8. doi: 10.1097/SMJ.0b013e3181fa5ec7.
The use of Yttrium microspheres to treat unresectable hepatoma is increasing worldwide. Therapeutically, Yttrium microspheres show promising increases in survival and tumor response, as well as acceptable toxicities. Here, we report on a 67-year-old man with hepatitis C-related advanced-stage hepatoma. This patient received selective internal radiation therapy (SIRT) using Yttrium microspheres (SIR-Spheres®). The patient displayed bone marrow suppression that resulted in a transient yet profound thrombocytopenia. To our knowledge, this is the first case of a hematologic complication as a consequence of the use of commercially available Yttrium microsphere devices.
在全球范围内，使用钇微球治疗不可切除肝癌的情况正在增加。在治疗方面，钇微球在提高生存率、肿瘤反应以及可接受的毒性方面显示出良好前景。在此，我们报告一名67岁患有丙型肝炎相关晚期肝癌的男性患者。该患者接受了使用钇微球（SIR-Spheres®）的选择性内放射治疗（SIRT）。患者出现骨髓抑制，导致短暂但严重的血小板减少。据我们所知，这是首例因使用市售钇微球装置而出现血液学并发症的病例。
